Let's empower the allergy community—together

Learn about an educational
AIT initiative

From start to sustained allergy relief^1-4

Introducing Allerthon, an initiative inspired by the commitment it takes to help manage allergies with allergen immunotherapy (AIT).

Allerthon is designed to provide physicians and patients with educational tools that foster meaningful conversations and help patients go the distance for long-term allergy relief with AIT.^1-4

This material is intended for educational purposes only and does not promote any specific product.

Start strong by signing up for more information

All fields are required.

I have read and understand Stallergenes Greer's Privacy Policy and Terms and Conditions. By providing the information requested and checking this box, I authorize Stallergenes Greer US to send non-promotional educational communications by email regarding allergy education initiatives and resources.

I authorize Stallergenes Greer US to communicate with me via email about their products, services, resources, and programs. I understand that I may opt out at any time by using the unsubscribe link provided to me in future emails or a similar mechanism.

INDICATIONS
Allergenic extracts are indicated for skin test diagnosis and treatment (immunotherapy) of patients with seasonal and perennial allergies.

IMPORTANT SAFETY INFORMATION

WARNING: SEVERE ALLERGIC REACTIONS

Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis.
Do not administer allergenic extracts to patients with severe, unstable, or uncontrollable asthma.
Intended for use only by physicians who are experienced in the administration of allergenic extracts.
Observe patients in the office for at least 30 minutes following treatment. Emergency measures and personnel trained in their use must be available immediately in the event of a life-threatening reaction.
Immunotherapy may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a systemic allergic reaction.
Allergenic extracts may not be suitable for patients receiving medications such as beta-blockers that may make them unresponsive to epinephrine or inhaled bronchodilators.

Do not inject intravenously. Initial dose should be based on skin test reactivity.

Systemic reactions include generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema, chest tightness and hypotension. Other adverse reactions include local reactions at the injection site (e.g., erythema, itching, swelling, tenderness, and pain). Additional symptoms that are not usually associated with allergy also may occur, such as nausea, emesis, abdominal cramps and diarrhea.

References: 1. Kucuksezer UC, Ozdemir C, Cevhertas L, Ogulur I, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy and allergen tolerance. Allergol Int. 2020;69(4):549-560. 2. Bousquet J, Khaltaev N, Cruz AA, et al; World Health Organization. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(suppl 86):8-160. 3. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(suppl 1):S1-S55. 4. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341(7):468-475.